Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

The European Melanoma Registry

EUMelaReg collects real-world data from melanoma patients throughout Europe and securely integrates these datasets in a common database.

Geographical coverage

Geographical coverage


Datasets available


Participating countries

News & Events

Patients with NMSC – a registry-based cohort study

EUMelaReg has started a registry-based cohort study and presented an e-poster at EADO 2023 on “Modern Treatment Usage and Outcome of Patients with Advanced Non-Melanoma Skin Cancer (NMSC) – a Registry...

EMR Project on acral lentiginous melanoma (ALM) at EADO 2023

At the EUMelaReg SDAC & IDC Retreat, a project was discussed, which was presented as an e-poster at the EADO congress: “Acral lentiginous melanoma shows a poorer response to immune checkpoint inhibiti...

EUMelaReg Expert Reception at EADO 2023


Learn more about our European initiative with its new registry entities BCC and SCC and find out more about our study concept on advanced and high-risk NMSC patie...

EUMelaReg SDAC & IDC Retreat

At the end of February 2023, after months of online exchange, there was finally the opportunity for a face-to-face meeting again. The two EUMelaReg committees SDAC (Scientific and Data Access) and IDC...

Bulgaria's first international project as full member of EUMelaReg

The Bulgarian Association of Dermato Oncology (BADO) invited Professor Michael Weichenthal to participate in its second National Congress of Dermato Oncology with international participation. During t...

Poster presentation at the International Congress of the Society for Melanoma Research in 2022

We are proud to report another successful international poster presentation on an European Melanoma Registry project. Following the two EUMelaReg projects EMR-SEQ and EMR-PD1, this year's Internationa...

EMR Non Melanoma Skin Cancer Registry is coming soon!

Besides our engagement in Melanoma Research, we will also focus on Research in Non Melanoma Skin Cancer, starting with BCCs and SCCs, in the near future. We are in the final stages of technical realiz...

Sheba Tel-HaShomer Medical Centre joined EUMelaReg

We are pleased to announce that Sheba Tel-HaShomer Medical Center, specifically the Ella Lemelbaum Institute for Immun-Oncology and Melanoma (which is part of the Sheba Cancer Research Centre) has joi...

Annual EUMelaReg Meeting on July 2nd, 2022

After two virtual meetings in the past two years, which were due to the COVID-19 pandemic, the EUMelaReg Annual Meeting was finally held face to face again this year. Although not everyone could be th...

Successful EMR-SEQ Poster presentation at ASCO 2022

Our first, already mentioned in the last newsletter, EUMelaReg abstract submission of the EMR-SEQ project (registry-based outcome analysis of 1,000 patients with BRAF V600 mutant metastatic melanoma i...

First EADO-EUMelaReg collaboration project and symposium

The collaboration between EMR and EADO is beginning to bear fruit: the survey on access to standard systemic treatment for metastatic melanoma launched within EADO and EMR was presented by Lidija Kand...

EMR - EADO Symposium in Seville

On Saturday, 23rd April, an EUMelaReg symposium chaired by Celeste Lebbé and Lidija Kandolf Sekulovic will be held. There will be three main topics: 1. "European Melanoma and NMSC registry“ presenting...

More than 8,100 cases in the European Melanoma Registry

We are very pleased to announce that as of today there are more than 8,100 documented, quality checked, cases in the European Melanoma Registry. This is an increase of about 15 % since the beginning o...

Abstracts submitted to ASCO 2022 and EADO 2022

For our EMRseq project an ASCO Abstract has been successfully submitted. EMRseq is a Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with...

More than 7,000 cases in the European Melanoma Registry

We are very pleased to announce that as of today there are more than 7,000 documented cases in the European Melanoma Registry. Both our new countries on board and the registers that have been involved...

Congratulation to CSEEMEG for documentation of more than 2,000 patients

We would like to take this opportunity and congratulate the Central South Eastern Europe Melanoma Expert Group (CSEEMEG), namely Serbia, Bosnia-Herzegowina, Croatia and Montenegro for their great cont...

EUMelaReg - EORTC cooperation

We are proud to announce that the European Melanoma Registry and the European Organisation for Research and Treatment of Cancer have entered into a cooperation agreement signed in September. With this...

Annual EUMelaReg Meeting on July 10th, 2021

On 10 July 2021, a successful virtual annual EUMelaReg meeting was held with broad participation of the EUMelaReg consortium members. Reported and lively discussed were activities, challenges and prog...

Montenegro joined EUMelaReg as country number 14 and strengthen the Central and South Eastern European Melanoma Expert Group

We have the pleasure to announce that Montenegro has joined EUMelaReg as 14th country. With its membership, Montenegro strenghtens the Central and South Eastern European Melanoma Expert Group. The rep...

Bulgaria joined EUMelaReg

Welcome aboard! We are happy to announce that the Bulgarian Association of Dermato-Oncology has joined the European Melanoma registry.

Second SDAC / IDC Retreat

After the success of the first SDAC & IDC retreat in Berlin last year, a second meeting (this time virtual) of both committees - Scientific Data Access (SDAC) and IT and Database (IDC) - took place in...

SDAC / IDC Retreat 2021

After the successful SDAC / IDC retreat this year, the next retreat of the two committees will take place in early 2021. To ensure a constant increase in data quality, the data quality standards must...

Italian Registry Joins EUMelaReg

Welcome aboard! We are happy to announce that the Italian team with Paolo Ascierto has joined our European initiative. We would also like to thank the Italian Melanoma Intergroup and Melanoma Foundati...

New Consortium Member from Switzerland

Welcome aboard! We are happy to announce that the Swiss Centre of Zurich with the team Prof. Dummer and Dr. Mangana joined our European Initiative. SwiMelaReg (Swiss Melanoma Registry) is running well...

First Patients in Romanian Melanoma Registry

News from the Romanian Melanoma Registry (RoMelaReg): One of our consortium members, the Romanian Oncological Society, has include its first patients into RoMelaReg.

Join us!

Collecting real-world data from melanoma patients across Europe, we aim to build the largest and quickest melanoma registry in the world. Interested societies or cancer treatment centres can help us by joining EUMelaReg – even without an existing registry.

“While the total number of cancer incidences is dropping, the number of cases of melanoma is increasing at a rate of 3-7% in many European countries. We need to analyse more data in order to improve diagnosis and develop novel therapies.”

Lidija Kandolf, Serbia

“A rapidly accumulating and massive high-quality real-life data can be obtained only when hands are joined. The conclusions we get from analysing such data allow us to better understand skin cancers and treatment effects. It allows us to formulate burning and important clinical questions and receive the results promptly, in real-time. This is a huge advantage that takes us one step further toward curing cancer. I'm proud to take part in this international collaborative project!”

Nethanel Asher, Israel

“Our advances and success in melanoma research are the result of a true team effort including international collaborations. World class cancer registries are highly needed for patient stratification strategies, as well as in order to translate the results of clinical trials in unselected patient populations and monitor patient care.”

Johanna Mangana, Switzerland

“Real-world data is crucial to validate clinical trial data. Generally, patients enrolled in clinical trials are selected in comparison to patients treated in real life (who are often in worse condition). Analysing data from a large number of real-life patients allows us to assess the true impact of new therapies in clinical practice. This is why a clinical registry such as the European Melanoma Registry is essential.”

Paolo Ascierto, Italy

“In recent years, we have witnessed revolutionary breakthroughs in treatment as well as rejuvenation of patients with melanoma, which poses new challenges for us. EUMelaReg has evolved into a valuable and even more powerful platform for in-depth analysis of clinical practice so far, enabling us to achieve better understanding and successful management of the condition. We are delighted to contribute to global knowledge with data from our real-world practice in Bulgaria.”

Iva Gavrilova, Bulgaria


Implementation of national registries

Provision of infrastructure

Data analysis through reknowned experts

Improved diagnosis and treatment



German Skin Cancer Society


Spanish Multidisciplinary Melanoma Group


Dutch Melanoma Treatment Registry


Danish Oncology Melanoma Database


Central South Eastern European Melanoma Expert Group


Romanian Melanoma Registry


Swiss Melanoma Registry


Polish Society of Surgical Oncology


Hellenic Society of Medical Oncology


Clinical National Melanoma Registry


Bulgarian Association of Dermato-Oncology

Ella Lemelbaum Institute for Immuno-Oncology and Melanoma


Albanian Melanoma Registry